Citigroup
MGX icon

Citigroup’s Metagenomi Therapeutics MGX Stock Holding History

Citigroup’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,314
Closed -$7.85K – 6545
2025
Q3 		$7.85K Sell
3,314
-2,129
-39% -$4.32K ﹤0.01% 5092
2025
Q2 		$8.06K Sell
5,443
-13,825
-72% -$21.6K ﹤0.01% 5221
2025
Q1 		$26.2K Sell
19,268
-2,318
-11% -$5.52K ﹤0.01% 5038
2024
Q4 		$77.9K Buy
21,586
+17,018
+373% +$41.1K ﹤0.01% 4942
2024
Q3 		$9.91K Buy
4,568
+3,178
+229% +$11K ﹤0.01% 5285
2024
Q2 		$5.67K Sell
1,390
-15,278
-92% -$105K ﹤0.01% 5242
2024
Q1 		$176K Buy
+16,668
New +$192K ﹤0.01% 4073

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup's MGX Position: Q4 2025 in Review

Citigroup sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 3,314 shares — an estimated $7.85K sold.

Citigroup first reported a position in MGX in Q1 2024 and held it in 7 quarters. The position peaked at $176K in Q1 2024. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Citigroup reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 3,314 Metagenomi Therapeutics shares in Q4 2025, an estimated $7.85K.
  • Citigroup first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 7 quarters.
  • Citigroup's Metagenomi Therapeutics position peaked at $176K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.